TFE3 and renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusions: Unfortunately, owing to the limited understanding of the underlying mechanisms10, the optimal therapy for TFE3-tRCC remains to be determined, prompting an urgent clinical need to molecularly characterize TFE3-tRCC.